TAKEDA PHARMACEUTICAL COMPANY LIMITED Takeda Pharmaceutical Company Limited Share Price Sapporo S.E.
Equities
4502
JP3463000004
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,300 JPY | -1.15% |
|
-.--% | +8.18% |
| 16/05 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
| 15/05 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
| Sales 2024 | 4,264B 27.15B 2,258B | Sales 2025 * | 4,108B 26.15B 2,175B | Capitalization | 6,486B 41.3B 3,435B |
|---|---|---|---|---|---|
| Net income 2024 | 144B 917M 76.29B | Net income 2025 * | 136B 864M 71.86B | EV / Sales 2024 | 1.54 x |
| Net Debt 2024 * | 3,771B 24.01B 1,997B | Net Debt 2025 * | 4,204B 26.77B 2,226B | EV / Sales 2025 * | 2.6 x |
| P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
45.8
x | Employees | - |
| Yield 2024 * |
4.55% | Yield 2025 * |
4.61% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
More news
| 1 month | +2.63% | ||
| 3 months | +4.62% | ||
| 6 months | -2.27% | ||
| Current year | +8.18% |
1 month
4 300.00
4 350.00
3 years
3 065.004 510.00
5 years
2 950.004 555.00
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 01/14/01 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/22/01 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 01/12/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 01/16/01 | |
Ian Clark
BRD | Director/Board Member | 62 | 01/19/01 |
Steven Gillis
BRD | Director/Board Member | 71 | 01/19/01 |
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
04/06/2024
- Sleep Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,134
JPY
Average target price
4,762
JPY
Spread / Average Target
+15.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.69% | 723B | |
| +34.28% | 595B | |
| -4.49% | 369B | |
| +20.24% | 332B | |
| +2.12% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| -0.35% | 168B |
- Stock Market
- Equities
- 4502 Stock
- 4502 Stock
